Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory J Dore

Showing results (181-190 of 404) with videos related to

Pageof 41
Sort By:
Journal of Clinical Virology Plus|June 29, 2022
Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infectionBeth Catlett, Mitchell Starr, Dorothy A Machalek, et al.
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
Journal of Gastroenterology and Hepatology|May 14, 2013
Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatmentJacqueline K Flynn, Gregory J Dore, Margaret Hellard, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
Antiviral Therapy|September 14, 2010
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in ThailandAnchalee Avihingsanon, Sharon R Lewin, Stephen Kerr, et al.
Hepatology (Baltimore, Md.)|September 18, 2016
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II studyMarianne Martinello, Edward Gane, Margaret Hellard, et al.
Journal of Gastroenterology and Hepatology|May 21, 2016
Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatmentBehzad Hajarizadeh, Jason Grebely, Hamish McManus, et al.
The Lancet Regional Health. Western Pacific|September 16, 2024
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, AustraliaShane Tillakeratne, Sallie-Anne Pearson, Maryam Alavi, et al.
The Journal of Infectious Diseases|January 30, 2020
Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to DiagnosisJason Grebely, Beth Catlett, Indika Jayasinghe, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Pageof 41

Showing results (181-190 of 404) with videos related to

Sort By:
Pageof 41
Journal of Clinical Virology Plus|June 29, 2022
Evaluation of serological assays for SARS-CoV-2 antibody testing from dried blood spots collected from cohorts with prior SARS-CoV-2 infectionBeth Catlett, Mitchell Starr, Dorothy A Machalek, et al.
AIDS (London, England)|May 29, 2004
Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohortW Phillip Law, Chris J Duncombe, Apicha Mahanontharit, et al.
Journal of Gastroenterology and Hepatology|May 14, 2013
Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatmentJacqueline K Flynn, Gregory J Dore, Margaret Hellard, et al.
AIDS (London, England)|October 3, 2003
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001W Phillip Law, Gregory J Dore, Chris J Duncombe, et al.
Antiviral Therapy|September 14, 2010
Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in ThailandAnchalee Avihingsanon, Sharon R Lewin, Stephen Kerr, et al.
Hepatology (Baltimore, Md.)|September 18, 2016
Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II studyMarianne Martinello, Edward Gane, Margaret Hellard, et al.
Journal of Gastroenterology and Hepatology|May 21, 2016
Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatmentBehzad Hajarizadeh, Jason Grebely, Hamish McManus, et al.
The Lancet Regional Health. Western Pacific|September 16, 2024
Trends in viral hepatitis liver-related morbidity and mortality in New South Wales, AustraliaShane Tillakeratne, Sallie-Anne Pearson, Maryam Alavi, et al.
The Journal of Infectious Diseases|January 30, 2020
Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to DiagnosisJason Grebely, Beth Catlett, Indika Jayasinghe, et al.
AIDS (London, England)|January 29, 2014
Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South AfricaNatasha K Martin, Angela Devine, Jeffrey W Eaton, et al.
Pageof 41